BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Exciting Early Results in Cynata’s UK Trial of iPSC-Derived MSC Therapeutic Product
Cynata Early Trial Results CYP-001

Exciting Early Results in Cynata’s UK Trial of iPSC-Derived MSC Therapeutic Product

January 28, 2018 By Cade Hildreth (CEO) Leave a Comment

 Patients in Cohort A Respond Well, 1st Patient in Cohort B Dosed in Cynata’s CYP-001 Trial

Cynata TherapeuticsAustralian stem cell company, Cynata Therapeutics has released exciting early results from its ongoing clinical trial in the UK utilizing an iPS cell-derived mesenchymal stem cell (MSC) therapeutic product.

Discover class-defining bioproduction tools.

The completion of the Day 28 visit of its last patient (8th overall) in Cohort A of the clinical trial triggered the planned independent Data Safety Monitoring Board (DSMB) review of data from this cohort.  As reported January 21st, 2018, the DSMB has completed its review and recommended that the trial should proceed to the next stage, i.e. to Cohort B.  Participants in Cohort B will receive twice (2x) the dose of patients in Cohort A.

Cynata Therapeutics also reported that the patients in Cohort A responded very well to CYP-001, with no treatment-related serious adverse events or safety concerns.  It is notable that 100% of participants showed a measurable and meaningful improvement in GvHD grade (severity).

While it is premature to draw robust conclusions about efficacy until the full results of the trial are analysed upon trial completion, these initial signs, especially at the lower of the two doses, are encouraging.  Recruitment of participants in Cohort B has now opened at 7 centres in the U.K. and Australia with our goal to complete the trial later this year.

Rooster DevServices

On January 24th, 2018, the company subsequently dosed the first patient in Cohort B of its ongoing Phase 1 clinical trial in acute steroid-resistant graft-versus-host disease.

To learn more, click here to read the full announcement from Cynata Therapeutics.

bitbio
Rate this post

Filed Under: iPS Cells, MSCs, Stem Cell News Tagged With: clinical trial, cynata therapeutics

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.